Sex-dependent rewarding effects of nicotine in mice are prevented by the atypical antipsychotic aripiprazole
Sex-dependent rewarding effects of nicotine in mice are prevented by the atypical antipsychotic aripiprazole
Brianis, R. C.; Bedeschi, L. G.; Iglesias, L. P.; Joca, S.; Aguiar, D. C.; Moreira, F. d. A.
AbstractNicotine stands amongst the most commonly used drugs in contemporary societies. Preparations for nicotine consumption range from traditional tobacco products (smoking) to modern electronic cigarettes (vaping). However, its rewarding and reinforcing effects vary as a function of dose and biological sex. In addition, few treatments exists for nicotine use disorders Here we sought to characterize the effects of nicotine on anxiety in the elevated plus maze (EPM) and reward in the conditioned place preference (CPP) paradigm in male and female mice and test the hypothesis that aripiprazole, a partial dopamine agonist, prevents nicotine-induced CPP. Nicotine effects were tested at 0.25, 0.5 and 1 mg/kg. The highest dose reduced basal locomotion in both males and females exposed to the open field and reduced open arm exploration in males in the EPM. Thus, the apparent anxiogenic-like effect is confounded by a reduction in basal exploratory activity. In the CPP paradigm, nicotine 0.5 mg/kg served as a reward conditioned stimulus in males, but not females. Finally, aripiprazole (0.1, 1 and 10 mg/kg) consistently prevented the acquisition of nicotine (0.5 mg/kg) CPP in males. These findings show a sexually dimorphic effect of nicotine in mice and suggest the antipsychotic aripiprazole as a potential pharmacological approach for reducing nicotine reward.